CD4 and neoplasm: With their large amounts of characterized and uncharacterized T-cell epitopes available for activating CD4+ T helper (Th) and CD8+ cytotoxic lymphocytes (CTLs) simultaneously, whole-tumor antigens in tumor cells represent an attractive alternative source of antigens to full-length recombinant tumor proteins and tumor-derived peptides [7,8].